Search

Supplemental material, sj-pdf-1-vet-10.1177_03009858211069126 for Medullary bone in male budgerigars (Melopsittacus undulatus) with testicular neoplasms by Nathan K. Hoggard and Linden E. Craig in Veterinary Pathology

Standardization of tumor assessment lays the foundation for validation of grading systems, permits reproducibility of oncologic studies among investigators, and increases confidence in the significance of study results. Currently, there is minimal methodological standardization for assessing tumors in veterinary medicine, with few attempts to validate published protocols and grading schemes. The current article attempts to address these shortcomings by providing standard guidelines for tumor assessment parameters and protocols for evaluating specific tumor types. More detailed information is available in the Supplemental Files, the intention of which is 2-fold: publication as part of this commentary, but more importantly, these will be available as “living documents” on a website (www.vetcancerprotocols.org), which will be updated as new information is presented in the peer-reviewed literature. Our hope is that veterinary pathologists will agree that this initiative is needed, and will contribute to and utilize this information for routine diagnostic work and oncologic studies. Journal editors and reviewers can utilize checklists to ensure publications include sufficient detail and standardized methods of tumor assessment. To maintain the relevance of the guidelines and protocols, it is critical that the information is periodically updated and revised as new studies are published and validated with the intent of providing a repository of this information. Our hope is that this initiative (a continuation of efforts published in this journal in 2011) will facilitate collaboration and reproducibility between pathologists and institutions, increase case numbers, and strengthen clinical research findings, thus ensuring continued progress in veterinary oncologic pathology and improving patient care. Accepted version

In this article, we reported a case of spinal muscular atrophy (SMA) type I noted to have tetraventricular hydrocephalus with Blake's pouch cyst at 8 months of age following intrathecal nusinersen therapy. The association of hydrocephalus with SMA is rarely reported in the literature. Development of hydrocephalus after intrathecal nusinersen therapy is also reported in some cases, but a cause–effect relationship is not yet established. The aim of this study was to describe the clinical characteristics of a patient with SMA type I and hydrocephalus, to review similar cases reported in the literature, and to explore the relationship between nusinersen therapy and development of hydrocephalus. The clinical presentation and radiographic findings of the patient are described and a comprehensive review of the literature was conducted. The adverse effect of communicating hydrocephalus related to nusinersen therapy is being reported and the authors suggest carefully monitoring for features of hydrocephalus developing during the course of nusinersen therapy.

Supplemental Material, sj-pdf-9-vet-10.1177_03009858211013712 for International Guidelines for Veterinary Tumor Pathology: A Call to Action by Donald J. Meuten, Frances M. Moore, Taryn A. Donovan, Christof A. Bertram, Robert Klopfleisch, Robert A. Foster, Rebecca C. Smedley, Michael J. Dark, Milan Milovancev, Paul Stromberg, Bruce H. Williams, Marc Aubreville, Giancarlo Avallone, Pompei Bolfa, John Cullen, Michelle M. Dennis, Michael Goldschmidt, Richard Luong, Andrew D. Miller, Margaret A. Miller, John S. Munday, Paola Roccabianca, Elisa N. Salas, F. Yvonne Schulman, Renee Laufer-Amorim, Midori G. Asakawa, Linden Craig, Nick Dervisis, D. Glen Esplin, Jeanne W. George, Marlene Hauck, Yumiko Kagawa, Matti Kiupel, Keith Linder, Kristina Meichner, Laura Marconato, Michelle L. Oblak, Renato L. Santos, R. Mark Simpson, Harold Tvedten and Derick Whitley in Veterinary Pathology

Supplemental Material, sj-pdf-5-vet-10.1177_03009858211013712 for International Guidelines for Veterinary Tumor Pathology: A Call to Action by Donald J. Meuten, Frances M. Moore, Taryn A. Donovan, Christof A. Bertram, Robert Klopfleisch, Robert A. Foster, Rebecca C. Smedley, Michael J. Dark, Milan Milovancev, Paul Stromberg, Bruce H. Williams, Marc Aubreville, Giancarlo Avallone, Pompei Bolfa, John Cullen, Michelle M. Dennis, Michael Goldschmidt, Richard Luong, Andrew D. Miller, Margaret A. Miller, John S. Munday, Paola Roccabianca, Elisa N. Salas, F. Yvonne Schulman, Renee Laufer-Amorim, Midori G. Asakawa, Linden Craig, Nick Dervisis, D. Glen Esplin, Jeanne W. George, Marlene Hauck, Yumiko Kagawa, Matti Kiupel, Keith Linder, Kristina Meichner, Laura Marconato, Michelle L. Oblak, Renato L. Santos, R. Mark Simpson, Harold Tvedten and Derick Whitley in Veterinary Pathology

Supplemental Material, sj-pdf-4-vet-10.1177_03009858211013712 for International Guidelines for Veterinary Tumor Pathology: A Call to Action by Donald J. Meuten, Frances M. Moore, Taryn A. Donovan, Christof A. Bertram, Robert Klopfleisch, Robert A. Foster, Rebecca C. Smedley, Michael J. Dark, Milan Milovancev, Paul Stromberg, Bruce H. Williams, Marc Aubreville, Giancarlo Avallone, Pompei Bolfa, John Cullen, Michelle M. Dennis, Michael Goldschmidt, Richard Luong, Andrew D. Miller, Margaret A. Miller, John S. Munday, Paola Roccabianca, Elisa N. Salas, F. Yvonne Schulman, Renee Laufer-Amorim, Midori G. Asakawa, Linden Craig, Nick Dervisis, D. Glen Esplin, Jeanne W. George, Marlene Hauck, Yumiko Kagawa, Matti Kiupel, Keith Linder, Kristina Meichner, Laura Marconato, Michelle L. Oblak, Renato L. Santos, R. Mark Simpson, Harold Tvedten and Derick Whitley in Veterinary Pathology

Supplemental Material, sj-pdf-6-vet-10.1177_03009858211013712 for International Guidelines for Veterinary Tumor Pathology: A Call to Action by Donald J. Meuten, Frances M. Moore, Taryn A. Donovan, Christof A. Bertram, Robert Klopfleisch, Robert A. Foster, Rebecca C. Smedley, Michael J. Dark, Milan Milovancev, Paul Stromberg, Bruce H. Williams, Marc Aubreville, Giancarlo Avallone, Pompei Bolfa, John Cullen, Michelle M. Dennis, Michael Goldschmidt, Richard Luong, Andrew D. Miller, Margaret A. Miller, John S. Munday, Paola Roccabianca, Elisa N. Salas, F. Yvonne Schulman, Renee Laufer-Amorim, Midori G. Asakawa, Linden Craig, Nick Dervisis, D. Glen Esplin, Jeanne W. George, Marlene Hauck, Yumiko Kagawa, Matti Kiupel, Keith Linder, Kristina Meichner, Laura Marconato, Michelle L. Oblak, Renato L. Santos, R. Mark Simpson, Harold Tvedten and Derick Whitley in Veterinary Pathology

Supplemental Material, sj-pdf-7-vet-10.1177_03009858211013712 for International Guidelines for Veterinary Tumor Pathology: A Call to Action by Donald J. Meuten, Frances M. Moore, Taryn A. Donovan, Christof A. Bertram, Robert Klopfleisch, Robert A. Foster, Rebecca C. Smedley, Michael J. Dark, Milan Milovancev, Paul Stromberg, Bruce H. Williams, Marc Aubreville, Giancarlo Avallone, Pompei Bolfa, John Cullen, Michelle M. Dennis, Michael Goldschmidt, Richard Luong, Andrew D. Miller, Margaret A. Miller, John S. Munday, Paola Roccabianca, Elisa N. Salas, F. Yvonne Schulman, Renee Laufer-Amorim, Midori G. Asakawa, Linden Craig, Nick Dervisis, D. Glen Esplin, Jeanne W. George, Marlene Hauck, Yumiko Kagawa, Matti Kiupel, Keith Linder, Kristina Meichner, Laura Marconato, Michelle L. Oblak, Renato L. Santos, R. Mark Simpson, Harold Tvedten and Derick Whitley in Veterinary Pathology

Supplemental Material, sj-pdf-8-vet-10.1177_03009858211013712 for International Guidelines for Veterinary Tumor Pathology: A Call to Action by Donald J. Meuten, Frances M. Moore, Taryn A. Donovan, Christof A. Bertram, Robert Klopfleisch, Robert A. Foster, Rebecca C. Smedley, Michael J. Dark, Milan Milovancev, Paul Stromberg, Bruce H. Williams, Marc Aubreville, Giancarlo Avallone, Pompei Bolfa, John Cullen, Michelle M. Dennis, Michael Goldschmidt, Richard Luong, Andrew D. Miller, Margaret A. Miller, John S. Munday, Paola Roccabianca, Elisa N. Salas, F. Yvonne Schulman, Renee Laufer-Amorim, Midori G. Asakawa, Linden Craig, Nick Dervisis, D. Glen Esplin, Jeanne W. George, Marlene Hauck, Yumiko Kagawa, Matti Kiupel, Keith Linder, Kristina Meichner, Laura Marconato, Michelle L. Oblak, Renato L. Santos, R. Mark Simpson, Harold Tvedten and Derick Whitley in Veterinary Pathology

Supplemental Material, sj-pdf-10-vet-10.1177_03009858211013712 for International Guidelines for Veterinary Tumor Pathology: A Call to Action by Donald J. Meuten, Frances M. Moore, Taryn A. Donovan, Christof A. Bertram, Robert Klopfleisch, Robert A. Foster, Rebecca C. Smedley, Michael J. Dark, Milan Milovancev, Paul Stromberg, Bruce H. Williams, Marc Aubreville, Giancarlo Avallone, Pompei Bolfa, John Cullen, Michelle M. Dennis, Michael Goldschmidt, Richard Luong, Andrew D. Miller, Margaret A. Miller, John S. Munday, Paola Roccabianca, Elisa N. Salas, F. Yvonne Schulman, Renee Laufer-Amorim, Midori G. Asakawa, Linden Craig, Nick Dervisis, D. Glen Esplin, Jeanne W. George, Marlene Hauck, Yumiko Kagawa, Matti Kiupel, Keith Linder, Kristina Meichner, Laura Marconato, Michelle L. Oblak, Renato L. Santos, R. Mark Simpson, Harold Tvedten and Derick Whitley in Veterinary Pathology

Supplemental Material, sj-pdf-2-vet-10.1177_03009858211013712 for International Guidelines for Veterinary Tumor Pathology: A Call to Action by Donald J. Meuten, Frances M. Moore, Taryn A. Donovan, Christof A. Bertram, Robert Klopfleisch, Robert A. Foster, Rebecca C. Smedley, Michael J. Dark, Milan Milovancev, Paul Stromberg, Bruce H. Williams, Marc Aubreville, Giancarlo Avallone, Pompei Bolfa, John Cullen, Michelle M. Dennis, Michael Goldschmidt, Richard Luong, Andrew D. Miller, Margaret A. Miller, John S. Munday, Paola Roccabianca, Elisa N. Salas, F. Yvonne Schulman, Renee Laufer-Amorim, Midori G. Asakawa, Linden Craig, Nick Dervisis, D. Glen Esplin, Jeanne W. George, Marlene Hauck, Yumiko Kagawa, Matti Kiupel, Keith Linder, Kristina Meichner, Laura Marconato, Michelle L. Oblak, Renato L. Santos, R. Mark Simpson, Harold Tvedten and Derick Whitley in Veterinary Pathology

Supplemental Material, sj-pdf-3-vet-10.1177_03009858211013712 for International Guidelines for Veterinary Tumor Pathology: A Call to Action by Donald J. Meuten, Frances M. Moore, Taryn A. Donovan, Christof A. Bertram, Robert Klopfleisch, Robert A. Foster, Rebecca C. Smedley, Michael J. Dark, Milan Milovancev, Paul Stromberg, Bruce H. Williams, Marc Aubreville, Giancarlo Avallone, Pompei Bolfa, John Cullen, Michelle M. Dennis, Michael Goldschmidt, Richard Luong, Andrew D. Miller, Margaret A. Miller, John S. Munday, Paola Roccabianca, Elisa N. Salas, F. Yvonne Schulman, Renee Laufer-Amorim, Midori G. Asakawa, Linden Craig, Nick Dervisis, D. Glen Esplin, Jeanne W. George, Marlene Hauck, Yumiko Kagawa, Matti Kiupel, Keith Linder, Kristina Meichner, Laura Marconato, Michelle L. Oblak, Renato L. Santos, R. Mark Simpson, Harold Tvedten and Derick Whitley in Veterinary Pathology

Purpose Infection by Human Herpes Viruses (HHV) types 1–3, are prevalent throughout the world. It is known that radiotherapy can reactivate HHVs, but it is unclear how and to what extent reactivations can interact with or affect radiotherapeutic efficacy, patient outcomes and mortality risk. Herein, we aim to summarize what is known about Herpes Simplex Virus (HSV)-1,2 and Varicella Zoster Virus (VZV) pathophysiology as it relates to tumor biology, radiotherapy, chemo-radiotherapy, diagnosis and management so as to optimize cancer treatment in the setting of active HHV infection. Our secondary aim is to emphasize the need for further research to elucidate the potential adverse effects of active HHV infection in irradiated tumor tissue and to design optimal management strategies to incorporate into cancer management guidelines. Materials and methods The literature regarding herpetic infection, herpetic reactivation, and recurrence occurring during radiotherapy and that regarding treatment guidelines for herpetic infections are reviewed. We aim to provide the oncologist with a reference for the infectious dangers of herpetic reactivation in patients under their care and well established methods for prevention, diagnosis, and treatment of such infections. Pain management is also considered. Conclusions In the radiotherapeutic setting, serologic assays for HSV-1 and HSV-2 are feasible and can alert the clinician to patients at risk for viral reactivation. RT-PCR is specific in identifying the exact viral culprit and is the preferred diagnostic method to measure interventional efficacy. It can also differentiate between herpetic infection and radionecrosis. The MicroTrak® HSV1/HSV2/VZV staining kit has high sensitivity and specificity in acute lesions, is also the most rapid means to confirm diagnosis. Herpetic reactivation and recurrences during radiotherapy can cause interruptions, cessations, or prolongations of the radiotherapeutic course, thus decreasing the biologically effective dose, to sub-therapeutic levels. Active HHV infection within the treatment volume results in increased tumor radio-resistance and potentially sub-therapeutic care if left untreated. Visceral reactivations may result in fatality and therefore, a high index of suspicion is important to identify these active infections. The fact that such infections may be mistaken for acute and/or late radiation effects, leading to less than optimal treatment decisions, makes knowledge of this problem even more relevant. To minimize the risk of these sequelae, prompt anti-viral therapy is recommended, lasting the course of radiotherapy.

Purpose Dilated superior ophthalmic vein (SOV) is an uncommon radiographic finding. The authors review the presentation, etiology, radiography, and visual implications of 113 patients with dilated SOV. Methods An observational case series and multicenter retrospective chart review were conducted. There were 113 patients with a dilated SOV. Outcome measures included patient demographics, clinical features, radiographic findings, diagnosis, and treatment, and treatment outcomes were assessed. Results Cases included 75 women (66%) and 38 men (34%) with a mean age of 49 ± 24 years (range, 0.4-90 years). Diagnoses fell under 6 categories: vascular malformation (n = 92, 81%), venous thrombosis (n = 11, 10%), inflammatory (n = 6, 5%), traumatic hemorrhage (n = 2, 2%), lymphoproliferative (n = 1, 1%), and infectious (n = 1, 1%). Imaging modalities utilized included MRI (n = 98, 87%), digital subtraction angiography (n = 77, 68%), CT (n = 29, 26%), and ultrasonography (n = 4, 4%). Disease status at last follow up included no evidence of disease (n = 57, 50%), alive with persistent disease (n = 53, 47%), and expired from disease (n = 3, 3%). Treatment and management was tailored to the underlying disease process with a mean follow up of 18 months (range, 1 day to 180 months). Visual impairment observed at presentation and last follow up across all cases was 26% and 22%, respectively. Conclusion Dilated SOV is a rare radiographic finding resulting from a wide spectrum of etiologies with clinical implications ranging from benign to sight- and life-threatening. Dilated SOV is most often found with dural-cavernous fistula or carotid-cavernous fistula, orbital or facial arteriovenous malformation, and venous thrombosis. Recognition of this finding and management of the underlying condition is critical.